Loading organizations...
§ Private Profile · Palo Alto, CA, USA
Biopharmaceutical company developing and manufacturing one-time gene therapies for prevalent chronic diseases like diabetes and severe.
Kriya Therapeutics is a biopharmaceutical company developing and manufacturing one-time gene therapies for prevalent chronic diseases, based in Durham, North Carolina. The company has secured over $1.2 billion in total funding to date, including a $320 million Series D round and a $270 million Series C financing completed in January 2022, alongside a recent $100 million advance to further its pipeline. Kriya integrates advanced manufacturing technologies and computational tools, such as the SIRVE platform for vector design and analysis, aiming to revolutionize gene therapy design and delivery. Their focus is on highly serious conditions like diabetes and severe obesity, leveraging their integrated development capabilities. Lead investors include QVT, Foresite Capital, and Narya Capital, with notable support from Vivek Ramaswamy. Kriya Therapeutics was founded in 2019 by Shankar Ramaswamy, Roger Jeffs, and Fraser Wright.
Kriya Therapeutics has raised $920.5M across 5 funding rounds.
Kriya Therapeutics has raised $920.5M in total across 5 funding rounds.
Kriya Therapeutics has raised $920.5M in total across 5 funding rounds.
Kriya Therapeutics's investors include Jim Momtazee, Akshay Rai, Aleph VC, Founders Fund, MizMaa Ventures, Sequoia Capital, Zeev Capital, Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund.
Kriya Therapeutics has raised $920.5M across 5 funding rounds. Most recently, it raised $320.0M Series D in August 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2025 | $320M Series D | JIM Momtazee, Akshay RAI | Aleph VC, Founders Fund, MizMaa Ventures, Sequoia Capital, Zeev Capital | Announced |
| Aug 16, 2023 | $150M Series C | JIM Momtazee | — | Announced |
| May 16, 2022 | $270M Series C | JIM Momtazee | Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT, Transhuman Capital | Announced |
| Jul 14, 2021 | $100M Series B | JIM Momtazee | Alumni Ventures, Amplo, Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, Hongkou, JDRF, Narya Capital, QVT, Transhuman Capital, Woodline Partners | Announced |
| May 12, 2020 | $80.5M Series A | — | — | Announced |
Kriya Therapeutics is a clinical-stage biopharmaceutical company developing gene therapies for chronic diseases in ophthalmology, metabolic disease, and neurology, targeting conditions affecting millions worldwide.[1][2][3] Its mission is to revolutionize medicine by eliminating human suffering and making genetic medicines accessible to the many, supported by a fully integrated manufacturing and R&D platform that enables parallel advancement of a broad pipeline, including programs like KRIYA-825 for Geographic Atrophy, Thyroid Eye Disease, Type 1 Diabetes, Metabolic Associated Steatohepatitis (MASH), and Trigeminal Neuralgia.[1][3][4] With over $600 million raised, including a $320 million Series D in recent years, and operations in Research Triangle Park, North Carolina (since 2019) and Palo Alto, California, Kriya demonstrates strong growth momentum through multiple clinical trials and presentations at major conferences like ARVO and ASGCT in 2025.[1][2][3][4]
Kriya Therapeutics was founded by pioneers in the biopharmaceutical industry, including Co-Founder and CEO Shankar Ramaswamy, M.D., with a vision to integrate advanced manufacturing technologies, computational tools, and development capabilities to revolutionize gene therapy design, development, and production.[5][6] Established around 2019, when it arrived in Research Triangle Park, the company emerged to address manufacturing constraints limiting gene therapies for prevalent diseases, building on proprietary platforms like SIRVE™ for rational vector design and STRIPE™ for scalable, low-cost production.[2][6] Early traction came via rapid fundraising—$100 million Series B followed by over $600 million total—including investor support from blue-chip life sciences and tech backers, enabling a diversified pipeline across metabolic, ophthalmic, and neurologic diseases.[4][6]
Kriya rides the gene therapy wave transforming medicine, accelerating durable treatments for chronic diseases amid FDA approvals for complement-targeted therapies in areas like Geographic Atrophy.[1][3] Perfect timing leverages manufacturing breakthroughs to overcome historical scalability barriers, enabling therapies for millions rather than rare cases, fueled by investor confidence in its CMC engine for large markets.[4][6] Market forces like rising demand for one-time curative gene therapies in ophthalmology, metabolism, and neurology favor Kriya, as it influences the ecosystem by setting new standards in cost-efficiency and parallel development, potentially expanding access and driving field-wide innovation.[3][5]
Kriya is poised to advance multiple clinical-stage programs, with near-term milestones like KRIYA-825 trial updates for Geographic Atrophy and expanded ASGCT/ARVO data sharing signaling pipeline momentum.[1][3] Trends in scalable AAV manufacturing and AI-enabled vector design will shape its trajectory, potentially yielding first approvals in high-prevalence diseases and further funding for neurology/metabolic expansions. Its influence may evolve from platform innovator to market leader, broadening gene therapy's reach and fulfilling its mission to end disease burdens for millions—positioning it as a biotech powerhouse in an era of accessible genetic medicine.[1][4][6]